TANAKA Junji
   Department   Other, Other
   Position  
Article types Original article
Language English
Peer review Peer reviewed
Title Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
Journal Formal name：International journal of hematology
Abbreviation：Int J Hematol
ISSN code：18653774/09255710
Domestic / ForeginForegin
Volume, Issue, Page 114(5),pp.608-619
Author and coauthor Kako Shinichi†, Hayakawa Fumihiko, Imai Kiyotoshi, Tanaka Junji, Mizuta Shuichi, Nishiwaki Satoshi, Kanamori Heiwa, Mukae Junichi, Ozawa Yukiyasu, Kondo Tadakazu, Fukuda Takahiro, Ichinohe Tatsuo, Ota Shuichi, Tanaka Yoshinori, Murayama Tohru, Kurahashi Shingo, Sakura Toru, Usui Noriko, Ohtake Shigeki, Kiyoi Hitoshi, Matsumura Itaru, Miyazaki Yasushi, Atsuta Yoshiko
Publication date 2021/11
Summary The optimal treatment for Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) has not been established in the high-intensity chemotherapy era. The outcomes of patients with Ph-negative ALL who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-matched related or unrelated donor in CR1 (HSCT-MRD group and HSCT-MUD group) were obtained from a Japanese registry database. Patients aged 16-24 years and 25-65 years were analyzed separately, and their outcomes were compared to those of patients who continued high-intensity chemotherapy in CR1 in studies (202U group and 202O group) by the Japan Adult Leukemia Study Group (JALSG). In the HSCT-MRD group, patients younger than 25 years had lower overall survival (OS) than the 202U group, presumably due to the higher non-relapse mortality (NRM) in the HSCT-MRD group. Patients 25 years and older had similar OS to the 202O group. The lower relapse rate was counterbalanced by higher NRM in the HSCT-MRD group. In the HSCT-MUD group, patients in both age groups had similar OS to their corresponding groups in the JALSG studies. In conclusion, high-intensity chemotherapy may change the role of HSCT for Ph-negative ALL.
DOI 10.1007/s12185-021-03198-4
PMID 34328634